Drug data last refreshed 38m ago · AI intelligence enriched 1w ago
ALUPENT is an inhaled small-molecule bronchodilator solution approved in 1980 for respiratory indications. The drug's mechanism of action and specific indications are not publicly detailed in available records, but inhalation formulations in this class typically target obstructive airway diseases. This is an established NDA product with a long commercial history.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team and focus on generic transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ALUPENT currently shows zero linked job openings and is in LOE-approaching phase, making it a low-opportunity asset for career growth at Boehringer Ingelheim. Roles on this product focus on protecting market share and managing the generic transition rather than driving expansion or innovation.
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.